GUBRA APS has a total of 16 patent applications. It decreased the IP activity by 85.0%. Its first patent ever was published in 2013. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are EVANS-FREKE STEPHEN, ASCENDIS PHARMA OPHTHALMOLOGY DIVISION AS and ALFACYTE LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Canada | 2 | |
#4 | Republic of Korea | 2 | |
#5 | United States | 2 | |
#6 | Brazil | 1 | |
#7 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Sugars | |
#5 | Climate change mitigation in goods production |
# | Name | Total Patents |
---|---|---|
#1 | Vrang Niels | 13 |
#2 | Jelsing Jacob | 10 |
#3 | Pedersen Søren Ljungberg | 9 |
#4 | Mannerstedt Karin Margareta Sophia | 8 |
#5 | Jensen Knud Jørgen | 7 |
#6 | Bech Esben Matzen | 6 |
#7 | Madsen Charlotte Stahl | 6 |
#8 | Kongsbak-Wismann Pernille | 4 |
#9 | Witteloostujn Mr Søren Blok Van | 3 |
#10 | Pedersen Soren Ljungberg | 3 |
Publication | Filing date | Title |
---|---|---|
EP3586876A1 | Glucose-sensitive peptide hormones | |
US2019336610A1 | Glucose-sensitive peptide hormones | |
KR20170078668A | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
EP3028711A1 | Molecular building blocks capable of assembling carbohydrate derivatives, fatty acid residues and peptides | |
EP2842965A1 | Neuromedin U analogs comprising serum albumin binding amino acid residue |